CureVac N.V. (CVAC) concluded trading on Wednesday at a closing price of $3.91, with 9.74 million shares of worth about $38.08 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -29.80% during that period and on May 22, 2024 the price saw a gain of about 18.84%. Currently the company’s common shares owned by public are about 223.99M shares, out of which, 91.77M shares are available for trading.
Stock saw a price change of 22.57% in past 5 days and over the past one month there was a price change of 50.38%. Year-to-date (YTD), CVAC shares are showing a performance of -7.13% which decreased to -59.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.21 but also hit the highest price of $12.36 during that period. The average intraday trading volume for CureVac N.V. shares is 780.08K. The stock is currently trading 33.98% above its 20-day simple moving average (SMA20), while that difference is up 33.19% for SMA50 and it goes to -20.98% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CureVac N.V. (NASDAQ: CVAC) currently have 223.99M outstanding shares and institutions hold larger chunk of about 7.96% of that.
The stock has a current market capitalization of $875.80M and its 3Y-monthly beta is at 2.60. It has posted earnings per share of -$1.27 in the same period. It has Quick Ratio of 2.43 while making debt-to-equity ratio of 0.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CVAC, volatility over the week remained 14.15% while standing at 9.09% over the month.
Stock’s fiscal year EPS is expected to rise by 29.61% while it is estimated to increase by 20.16% in next year. EPS is likely to grow at an annualized rate of -10.76% for next 5-years, compared to annual growth of -23.15% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on April 25, 2024 offering a Market perform rating for the stock and assigned a target price range of between $12 and $4 to it. Coverage by SVB Securities stated CureVac N.V. (CVAC) stock as an Outperform in their note to investors on June 08, 2023, suggesting a price target of $13 for the stock. On January 19, 2023, UBS Upgrade their recommendations, while on January 09, 2023, Jefferies Upgrade their ratings for the stock with a price target of $21. Stock get an Underperform rating from BofA Securities on January 21, 2022.
